On August 12, 2026, a new publication involving LL-37 appeared in the journal Cell Reports. The study is titled "Melanoma exosomal hsa-miR-221-5p suppresses keratinocyte LL-37 to promote tumor progression." LL-37 remains an unapproved compound used only in research settings. This publication is indexed under PubMed ID 42593966. The title indicates the study examines a relationship between melanoma-derived exosomal hsa-miR-221-5p and keratinocyte LL-37 in the context of tumor progression. No specific findings, data, or conclusions beyond the title are available in this brief. Readers interested in the details of the methodology or results should consult the original publication directly through the provided source link. As with all peptide research, LL-37 has not received regulatory approval for therapeutic use and is classified strictly for research purposes. This brief does not summarize or interpret the study's results, as only the title and journal information were provided. For additional background on LL-37, including its general research context and regulatory status, readers can refer to the compound overview.
New Publication on LL-37 and Melanoma in Cell Reports
Source: https://pubmed.ncbi.nlm.nih.gov/42593966/